Objective To investigate the expression of long non-coding RNA LINC00460 in lung adenocarcino-ma(LUAD)and its effects on cell proliferation and migration.Methods Quantitative real-time polymerase chain reaction(RT-qPCR)was used to detect the expression of LINC00460 in LUAD cell lines(PC-9,A549,NCI-H1975 and H1299)and normal lung cell line(MRC-5).LINC00460 was silenced in A549 and H1299 cells using small interfering RNA(siRNA),followed by cell proliferation assessment with CCK-8 assay and evaluation of cell migration capacity through the Transwell assay.Fluorescence in situ hybridization(FISH)and RNA immunoprecipitation(RIP)assays were performed to determine the subcellular localization of LINC00460 and its interaction with EZH2.Western blot was applied to examine EZH2 and H3K27me3 ex-pression in cells.Results LINC00460 was highly expressed in LUAD cells,and the expression level was sig-nificantly decreased after silencing(P＜0.001).Silencing LINC00460 markedly inhibited the proliferation and migration of A549 and H1299 cells(P＜0.001).LINC00460 was primarily localized in the nucleus.RIP assays confirmed a significant interaction between LINC00460 and EZH2(P＜0.001).Furthermore,the silencing of LINC00460 resulted in a significant reduction in the expression of EZH2 and its downstream target H3K27me3(P＜0.001).Conclusions LINC00460 is highly expressed in LUAD cells.Silencing LINC00460 inhibits cell proliferation and migration through EZH2.This mechanism provides a basis for LINC00460 as a potential therapeutic target in lung adenocarcinoma.

OBJECTIVE： To evaluate the efficacy and safety of icotinib in the treatment of advanced non-small cell lung cancer （NSCLC）， and to provide evidence-based reference for clinical drug use. METHODS： Retrieved from the Cochrane library， PubMed， Sciencedirect， CNKI， Wanfang database and VIP， RCTs about icotinib or icotinib combined with routine treatment or with other drugs （trial group） versus routine treatment or other drugs （control group） in the treatment of advanced NSCLC were collected. After literature screening， data extraction and literature quality evaluation with Cochrane collaboration bias risk assessment tool 5.1.0， Meta-analysis was performed by using Rev man 5.3 statistical software. RESULTS： A total of 27 RCTs were included， involving 2 345 patients. Results of Meta-analysis showed that response rate [OR＝1.64， 95％CI（1.36， 1.97）， P＜0.000 01] and disease control rate [OR＝1.68， 95％CI（1.39， 2.04）， P＜0.000 01] in trial group were significantly higher than control group； the incidence of ADR in trial group [OR＝0.59， 95％CI（0.48， 0.72）， P＜0.000 01] was significantly lower than control group. CONCLUSIONS： Icotinib shows good efficacy and safety in the treatment of advanced NSCLC.

Objective Through compare the clinical data of two kinds of coronary bypass operation under Extacorpeal circulation and Non extracorpoeal circulation in patients over 70 years old with triple-vessel disease, and to provide the clinicalexperience. Methods Choose the patients hospitalized from Department of thoracic sur-gery 115 cases who had had coronary arterybypass grafting surgery from January 2014 to June 2017.there were 51 cases accepted Extracorporeal circulation surgery,Another 64 cases accepted Non-extracorpoeal circulation sur-gery.And make a comparative study of the clinical data of two kinds of coronary bypass operation. Results Com-pared with the Extacorpeal circulation group,the operation time,bypass vessel numb,the Thoracic Drainage were no statistic difference in Non-extracorpoealcirculation(P>0.05),The amount of transfused blood;Mechanical ven-tilation time,Hospitalized time in ICU;Postoperative complications;Total hospitalization time were Significantly lower than Extacorpeal circulation group,the difference was statistically significant(P < 0.05). Conclusions As the development of technology and the maturity of the operator′s experience,Off-pump coronary artery bypass graft-ing is safe and effective in elderly patients,which could be further promoted in clinical practice.